Mineralys Therapeutics (MLYS) announced that it has commenced an underwritten public offering of $250M of shares of its common stock. Mineralys intends to use the net proceeds from the proposed offering to fund clinical development of lorundrostat, including research and development and manufacturing, and pre-commercialization activities, as well as for working capital and general corporate purposes. BofA Securities, Evercore, Goldman Sachs, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C. Wainwright & Co. is acting as co-manager for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Buy Rating Affirmed for Mineralys Therapeutics, Inc. Due to Promising Lorundrostat Study Outcomes
- Promising Potential of Lorundrostat Drives Buy Rating for Mineralys Therapeutics, Inc.
- Mineralys Therapeutics Reports Positive Phase 3 Trial Results
- Mineralys Therapeutics announces results from Launch-HTN, Advance-HTN trials
- Buy Rating for Mineralys Therapeutics, Inc. Driven by Lorundrostat’s Potential in Hypertension Treatment
Questions or Comments about the article? Write to editor@tipranks.com